Phylogica Limited (ASX: PYC) is into the business of biopharmaceuticals. The company utilises proprietary drug discovery technologies to develop novel peptide therapies. The company has recently via an ASX release declared that the first competitive in vivo evaluation of the intracellular delivery technology demonstrated the differentiation of the company’s CPP platform. Competitive in vivo evaluation is the primary driver of commercial outcomes because it informs the answer to the question of whether the results observed in animals are likely to translate into a product with a competitive advantage in humans.
The benefits of the CPP platform have been described in the vitro. The results clearly exhibit that those advantages do translate from better outcomes in the test tube to better results in a living organism. The results were obtained using a well-described experimental model of melanoma, which is known to be highly aggressive and difficult to treat. Mice were vaccinated before tumour inoculation, and the results demonstrate that Phylogica’s CPP-vaccination strategy generated an anti-tumour immune response directed against the melanoma. Importantly, this resulted in a more significant delay in tumour outgrowth (extended survival), compared to the competitor CPP. The peptide vaccine work described above was conducted in collaboration with Dr Jason Waithman of the Telethon Kids Institute.
The key Events and happenings during the timeline are briefed below: –
- In July 2018, Phylogica’s Scientific Advisory Board identified the importance of obtaining in vivo (animal model) evidence of the ability of the company’s Cell Penetrating Peptides (CPPs) to outperform competitive technologies to the company’s prospects of commercial success.
- The results described below represent the first in vivo competitive read-out of Phylogica’s CPP technology in relation to the company’s peptide vaccine program.
- Phylogica’s lead first generation CPP has out-performed a competitor CPP known as the ‘zebra’ peptide in vivo in a model of melanoma (cancer).
- CPPs derived from the viral Zebra protein are currently being progressed into clinical evaluation in the context of a peptide vaccine therapy in oncology.
Now, let us have a glance at Phylogica Limited’s stock performance and the return it has posted over the last few months. The stock is currently trading at a price of $0.030 and trading flat during the day’s trade, with a market capitalisation of ~$73.29 Million. The counter opened the day at $0.03, which was also the day’s high, with a daily volume of 1,769,450. The stock has provided a YTD return of 7.14% & also posted returns of -6.25%, -6.25% & 11.11% over the past six months, three & one-months period respectively. It had a 52-week high price of $0.038 and touched 52 weeks low of $0.020, with an average volume of 501,085 approximately.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.